Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about treatment/resistant depression
Recent news which mentions treatment/resistant depression
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
August 14, 2024
Tickers
ATAI
Tags
DMT/Assisted Therapy
Florian Brand
treatment/resistant depression
From
Benzinga
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
July 23, 2024
Tickers
JNJ
NEWS
Tags
Psychedeclis for TDR
Bill Martin
Benzinga
From
Benzinga
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
April 26, 2024
Tickers
NEWS
Tags
Rob Conley
Benzinga
Psychedelics
From
Benzinga
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
March 28, 2024
Tickers
ATAI
NEWS
Tags
Market News
ATAI
Cannabis
From
Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Tickers
CMPS
Tags
2023 financial results
COMP360
Biotech
From
Benzinga
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
November 15, 2023
Tickers
AWKNF
CMPS
Tags
AWKNF
Psilocybin program
Benzinga
From
Benzinga
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
October 03, 2023
Tickers
ATAI
Tags
Psychedelics
Benzinga
Penny Stocks
From
Benzinga
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
September 06, 2023
Tickers
CMPS
Tags
News
Management
treatment/resistant depression
From
Benzinga
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
August 24, 2023
Tickers
GHRS
Tags
Psychedelics
Benzinga
GHRS
From
Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
July 18, 2023
Tickers
CMPS
Tags
FDA
Psilocybin program
Psychedelics
From
Benzinga
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
July 05, 2023
Tickers
ATAI
CMPS
HTGC
Tags
Psychedelics
psilocybin therapies
Benzinga
From
Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
May 30, 2023
Tickers
CMPS
NUMIF
Tags
Psilocybin program
Psychedelics
Benzinga
From
Benzinga
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
May 11, 2023
Tickers
GHRS
Tags
Guidance
Psychedelic/Assisted Therapies
Small Cap
From
Benzinga
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
May 04, 2023
Tags
Biotech
Benzinga
General
From
Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
Tickers
ATAI
CMPS
IGXT
Tags
Market News
Cannabis
Markets
From
Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
December 12, 2022
Tickers
CMPS
Tags
CMPS
Cannabis
Markets
From
Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
December 09, 2022
Tickers
CMPS
Tags
Legal
Management
treatment/resistant depression
From
Benzinga
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
November 16, 2022
Tickers
CMPS
Tags
Psychedelics
Benzinga
News
From
Benzinga
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
November 02, 2022
Tags
Psychedelics
Contracts
Benzinga
From
Benzinga
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
October 05, 2022
Tickers
ATAI
Tags
Small Cap
DMT Clinical Trial
ATAI
From
Benzinga
Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
July 28, 2022
Tickers
CMPS
Tags
COMPASS Pathways PLC
Dr/ Walter Kaye
Global
From
Benzinga
Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows
April 12, 2022
Tags
Markets
Cannabis
Market News
From
Benzinga
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
Tickers
CMPS
Tags
Biotech
General
Benzinga
From
Benzinga
Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying
November 16, 2021
Tickers
GHRS
Tags
toad venom
Benzinga
Small Business
From
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.